Online Program Home
My Program

Legend:
CC = Vancouver Convention Centre   F = Fairmont Waterfront Vancouver
* = applied session       ! = JSM meeting theme

Activity Details

301 Tue, 7/31/2018, 8:30 AM - 10:20 AM CC-West 213
SPEED: Statistics for Biopharmaceutical Studies — Contributed Speed
Biopharmaceutical Section , Section on Bayesian Statistical Science
Chair(s): Michael M. Hoffman, Princess Margaret Cancer Centre/University of Toronto
Poster Presentations for this session.
8:35 AM Probabilistic Modeling of Sleep and Awake States in Alzheimer's Disease Cici Bauer, Pfizer, Inc ; Charmaine Demanuele, Pfizer, Inc. ; Dmitri Volfson, Pfizer
8:40 AM Integrative Statistical Analysis Pipeline for RNA-Seq and NanoString with Application to Gene Expression Data of Cancer Patients Jeea Choi, Novartis Pharmaceuticals ; Catarina D. Campbell, Novartis Institutes for BioMedical Research ; Xiaoshan Wang, Novartis Pharmaceuticals ; He Wei, Novartis Pharmaceuticals ; Robinson Douglas, Novartis Pharmaceuticals ; Stephane Wong, Novartis Pharmaceuticals ; Bin Fu, Novartis Pharmaceuticals ; Rebecca Leary, Novartis Institutes for BioMedical Research ; Kavitha Venkatesan, Novartis Institutes for BioMedical Research ; Ying A Wang, Novartis Pharmaceuticals
8:45 AM Bridging Information Between Dose-Response Curves Across Populations in Early Phase Clinical Trials Moreno Ursino, Inserm DR PA 6
8:50 AM A Simultaneous PK/PD Model for Muscle Relaxant Using Muscle Twitch Counts Elizabeth Sigworth ; Matthew S Shotwell, Vanderbilt University
8:55 AM STEPDOWN TESTING PROCEDURES for DOSE FINDING STUDY with ADAPTIVE DESIGN Gang Jia, Merck & Co.
9:00 AM Conditional Power Calculation for the Interim Monitoring of Cluster-Randomized Trials with Interval-Censored Endpoints Kaitlyn Cook, Harvard University ; Rui Wang, Harvard Pilgrim HealthCare Institute
9:05 AM Explore Modified Organ Dysfunction Score System to Improve the Prediction of Survival Grace Zhang, GSK
9:10 AM Discovering Biomarkers Jointly Modeled with Multiple Efficacy Variables in Early Phase Clinical Trials Danni Yu, Eli Lilly and Company
9:15 AM Extended Rank Tests for Analyzing Recurrent Event Data Qiang Zhao ; Mark Chang, Veristat ; Michael LaValley, Boston University ; Joseph M. Massaro, Boston University ; Bin Zhang, Seqirus ; Kathryn Lunetta, Boston University
9:20 AM A Study in the Use of Unsupervised Random Forest in the Analysis of Data Sets Composed of Categorical Variables/Features Nelson Lee Afanador, Merck ; Richard Baumgartner, Merck ; Dai Feng, Merck
9:30 AM A Statistical Evaluation of Cardiovascular Measurements Collected via Mobile Health Technology and Traditional Tools Qinlei Huang, Merck ; Lori Mixson, Merck
9:35 AM Method for Evaluating Longitudinal Follow-Up Frequency: Application to Dementia Research Leah Suttner, University of Pennsylvania ; Sharon X Xie, University of Pennsylvania
9:40 AM Performance Comparison of Post-Hoc Subgroup Search Algorithms for Clinical Trials Victor Talisa, University of Pittsburgh ; (Joyce) Chung-Chou H. Chang, University of Pittsburgh
9:45 AM Relationship Between ORR, PFS and OS in Patients Treated with Anti-PD1/PDL1 Therapies Jiabu Ye, AstraZeneca ; Pralay Mukhopadhyay, Astrazeneca ; Xiang Ji, AstraZeneca
9:50 AM Real-Time Study Milestone Projection in Clinical Trials with Time-To-Event Endpoints Yanping Liu, Merck & Co. ; Gang Jia, Merck & Co.
9:55 AM Sensitivity to Infusion and Blood Draw Time Recording Errors in Pharmacokinetic Modeling Hannah Weeks, Vanderbilt University ; Matthew S Shotwell, Vanderbilt University
10:00 AM A Testing Paradigm for Earl Biomedical Research with Many Correlated Tests Robert Montgomery ; Jonathan D Mahnken, University of Kansas Medical Center
10:05 AM Tobit Regression for Modeling Mean Survival Time Using Data Subject to Multiple Sources of Censoring Qi Gong, Gilead ; Douglas E. Schaubel, University of Michigan, Ann Arbor